Comment optimiser le taux sérique de vancomycine dans le traitement des infections à Staphylococcus aureus

[1]  P. Viale,et al.  The Antimicrobial Therapy Puzzle: Could Pharmacokinetic-Pharmacodynamic Relationships Be Helpful in Addressing the Issue of Appropriate Pneumonia Treatment in Critically Ill Patients? , 2006 .

[2]  É. Batard,et al.  Dosage des antibiotiques en réanimation : quand et comment demander et interpréter les tests ? , 2006 .

[3]  J. Carlet,et al.  Existe-t-il une alternative aux glycopeptides pour le traitement des infections à Staphylococcus aureus résistant à la méthicilline ? , 2006 .

[4]  A. Fraise,et al.  Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. , 2006, The Journal of antimicrobial chemotherapy.

[5]  M. Falagas,et al.  Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. , 2005, The Lancet. Infectious diseases.

[6]  R. Garraffo,et al.  Signification clinique des corrélations pharmacocinétique/pharmacodynamie des antibiotiques chez les patients de réanimation , 2005 .

[7]  Jerome J. Schentag,et al.  Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  G. Eliopoulos,et al.  Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia , 2004, Journal of Clinical Microbiology.

[9]  P. Ward,et al.  Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  S. Fridkin,et al.  Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Jerome J. Schentag,et al.  The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. , 2002, The Journal of antimicrobial chemotherapy.

[12]  K. Hiramatsu.  Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. , 2001, The Lancet. Infectious diseases.

[13]  Jerome J. Schentag,et al.  Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. , 2000, International journal of antimicrobial agents.

[14]  J. Perfect,et al.  Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin–dalfopristin in patients intolerant of or failing prior therapy , 2000 .

[15]  Jerome J. Schentag,et al.  Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[16]  A. MacGowan,et al.  Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. , 2000, The Journal of antimicrobial chemotherapy.

[17]  Charles G. Martin,et al.  Mississippi mud in the 1990s , 1998, Cancer.

[18]  Y. Fukuchi,et al.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin , 1997, The Lancet.

[19]  M. V. Miles,et al.  Special considerations for monitoring vancomycin concentrations in pediatric patients. , 1997, Therapeutic drug monitoring.

[20]  N. Saunders.  Vancomycin administration and monitoring reappraisal. , 1995, The Journal of antimicrobial chemotherapy.

[21]  G. Braden,et al.  Trough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  N. Saunders.  Why monitor peak vancomycin concentrations? , 1994, The Lancet.

[23]  Jerome J. Schentag,et al.  Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar , 1994, Antimicrobial Agents and Chemotherapy.

[24]  J. Kingdom,et al.  Vancomycin toxicity: a prospective study. , 1985, The Journal of antimicrobial chemotherapy.

[25]  B. Farber,et al.  Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981 , 1983, Antimicrobial Agents and Chemotherapy.

[26]  A. Bisno,et al.  Failure of vancomycin treatment in Staphylococcus aureus endocarditis. In vivo and in vitro observations. , 1976, JAMA.

[27]  M. Kitzis,et al.  Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[28]  M. Rybak,et al.  The pharmacokinetic and pharmacodynamic properties of vancomycin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .

[30]  A. MacGowan,et al.  Therapeutic monitoring of antimicrobials: a summary of the information presented at the UK NEQAS for antibiotic Assays meeting for participants, October 1993. , 1995, The Journal of antimicrobial chemotherapy.

[31]  Claude Carbón.  Impact of the antibiotic dosage schedule on efficacy in experimental endocarditis. , 1990, Scandinavian journal of infectious diseases. Supplementum.